Company Overview and News

 
BRIEF-Bruker Acquires Nanoir Company Anasys Instruments

2018-04-17 reuters
* BRUKER CORP - FINANCIAL DETAILS OF TRANSACTION WERE NOT DISCLOSED. Source text for Eikon: Further company coverage:
Upvote Downvote

 
BRKR / Bruker Corp. DEF 14A

2018-04-17 sec.gov
QuickLinks -- Click here to rapidly navigate through this document
Upvote Downvote

 
NN, Inc: ~50% Upside For Misunderstood Industrial

2018-03-20 seekingalpha
NN, Inc. is a serial acquirer and has built a track record of building a reputable set of businesses.
Upvote Downvote

2
BRKR / Bruker Corp. 10-K (Annual Report)

2018-03-16 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Upvote Downvote

 
Is the Tax Repeal Only Glitter and No Gold for MedTech?

2018-03-16 zacks
The medical device tax suspension up to Jan 1, 2020, is one of the very few amendments that have garnered the maximum number of bipartisan votes in the House.
Upvote Downvote

 
BRKR / Bruker Corp. 8-K (Current Report)

2018-03-14 sec.gov
UNITED STATES<
Upvote Downvote

 
Bruker (BRKR) Down 9.3% Since Earnings Report: Can It Rebound?

2018-03-12 zacks
It has been about a month since the last earnings report for Bruker Corporation (BRKR - Free Report) . Shares have lost about 9.3% in that time frame.
Upvote Downvote

 
BRKR / Bruker Corp. 8-K (Current Report)

2018-03-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISS
Upvote Downvote

 
BRIEF-Bruker Corp Buys High-Speed Qcl Infrared Microscopy Company Irm

2018-02-22 reuters
* BRUKER CORP - FINANCIAL DETAILS OF TRANSACTION WERE NOT DISCLOSED. Source text for Eikon: Further company coverage:
Upvote Downvote

 
BRIEF-Bruker Announces Resignation Of CFO And Appointment Of Principal Accounting Officer

2018-02-21 reuters
* BRUKER CORP - ANTHONY MATTACCHIONE, CHIEF FINANCIAL OFFICER, HAS SUBMITTED HIS RESIGNATION, EFFECTIVE AS OF MARCH 16, 2018
Upvote Downvote

 
BRKR / Bruker Corp. 8-K (Current Report)

2018-02-21 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934     Date of Report (Date of earliest event reported): February 16, 2018   BRUKER CORPORATION (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation)   000-30833 (Commission File Number)   04-3110160 (IRS Employer Identification No.
Upvote Downvote

 
BRKR / Bruker Corp. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) BRUKER CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 116794108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
Upvote Downvote

 
BRKR / Bruker Corp. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G/A (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) BRUKER CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 116794108 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
Upvote Downvote

 
Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View

2018-02-09 zacks
Bruker Corporation (BRKR - Free Report) reported adjusted earnings per share (EPS) of 51 cents in the fourth quarter of 2017, up 10.9% from the year-ago figure. Also, adjusted EPS beat the Zacks Consensus Estimate by a couple of cents.
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

2h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

CUSIP: 116794108